MOS Prebiotic Potential in Older Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotic Intervention on Gut Microbiota and Cognitive Functioning in Older Adults With a Mild Cognitive Impairment

NCT05859230

Mild Cognitive Impairment

UNKNOWN NA

The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women

NCT02445560

Aging

COMPLETED NA

The Effects of a Novel Probiotic on Gastrointestinal Health in Generally Healthy Adults

NCT05595980

Gastrointestinal Health Immune Health Digestive Health

COMPLETED NA

The Effect of a Prebiotic, Probiotic and Synbiotic on the Gut Microbiota and Immune Response of Older Volunteers (GOS)

NCT01586247

Gut Microbiota Immune Function

COMPLETED NA

In Vivo Human Study on Commercial Cellobiose as a Potential Prebiotic Candidate

NCT07097389

Gut -Microbiota As a Preliminary Study, Healthy Population's Gut Microbiota is Studied to See if Cellobiose Supplementation is Altering the Microbial Community or Not

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mannooligosaccharides

Mannooligosaccharides yeast extract

Group Type EXPERIMENTAL

Mannooligosaccharides yeast extract

Intervention Type DIETARY_SUPPLEMENT

15 g per day of mannooligosaccharide yeast extract.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mannooligosaccharides yeast extract

15 g per day of mannooligosaccharide yeast extract.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults 50-99 years of age.
* Able to provide written informed consent in English.
* Willingness to complete all study procedures
* Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion Criteria

* Yeast allergy.
* Self-reported kidney disease.
* Elite athletes or long-distance runners.
* Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
* Current use of laxatives or antidiarrheal medications.
* Use of other investigational products within 3 months of the screening visit.
* Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
* Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
* Current cancer treatment
* Currently pregnant

Minimum Eligible Age

50 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes